Defunct Company
Total Trials
6
As Lead Sponsor
As Collaborator
0
Total Enrollment
3,710
NCT01130272
Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea
Phase: Phase 2
Role: Lead Sponsor
Start: Apr 28, 2010
Completion: Jul 14, 2011
NCT01128530
Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)
Start: Jun 30, 2010
Completion: Jan 31, 2011
NCT01198626
Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia
Start: Oct 31, 2010
Completion: Oct 31, 2011
NCT01279590
Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)
Start: Mar 31, 2011
Completion: Nov 30, 2011
NCT01553591
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
Phase: Phase 3
Start: May 29, 2012
Completion: Jul 29, 2014
NCT01553747
Completion: Jan 9, 2014